OncoMatch/Clinical Trials/NCT06799026
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
Is NCT06799026 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including GM-CSF and DC/MM Fusion Vaccine for multiple myeloma.
Treatment: Elranatamab · GM-CSF · DC/MM Fusion Vaccine — This research is being done to determine if the combination of the Dendritic Cell (DC)/ Multiple Myeloma (MM) fusion vaccine with elranatamab is safe and effective in treating Relapsed or Refractory Multiple Myeloma (MM). The names of the study drugs and vaccine involved in this study are: * DC/MM fusion vaccine (a personalized cancer vaccine in which harvested participant tumor cells are fused with harvested participant dendritic blood cells) * Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) (a type of growth factor) * Elranatamab (a type of T-cell engager antibody)
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: proteasome inhibitor
relapsed following or are refractory to proteasome inhibitors
Must have received: IMiD
relapsed following or are refractory to IMiDs
Must have received: anti-CD38 monoclonal antibody
relapsed following or are refractory to ... anti-CD38 mAb therapy
Cannot have received: PD-1 antibody
Exception: only if experienced toxicities resulting in treatment discontinuation
Patients who previously received PD-1 antibody and have experienced toxicities resulting in treatment discontinuation
Cannot have received: organ transplant requiring immunosuppressive therapy
Prior organ transplant requiring immunosuppressive therapy
Lab requirements
Blood counts
ANC > 1K/uL; Platelets > 50 K/uL without transfusional support
Kidney function
Creatinine clearance ≥ 40 mL/min for participants with creatinine levels above institutional normal
Liver function
Total bilirubin ≤1.5 x institutional upper limit of normal; AST ≤ 3 x institutional upper limit of normal; ALT ≤ 3 x institutional upper limit of normal
Total bilirubin ≤1.5 x institutional upper limit of normal; AST ≤ 3 x institutional upper limit of normal; ALT ≤ 3 x institutional upper limit of normal; Creatinine clearance ≥ 40 mL/min for participants with creatinine levels above institutional normal; ANC > 1K/uL; Platelets > 50 K/uL without transfusional support
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Beth Israel Deaconess Medical Center · Boston, Massachusetts
- Dana-Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify